Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:45 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
NCT01273181 · National Cancer Institute (NCI) · PHASE1/PHASE2 · terminated · last registry update 2015-10-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL2RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-08-03Results posted on the registry: Armando Torres Ramírez, Tacrolimus with rapid steroid withdrawal + Tacrolimus with steroids minimization (NCT01002339)
- 2016-07-22Results posted on the registry: National Cancer Institute (NCI), Anti-VEGFR2 CAR CD8 plus PBL + Cyclophosphamide (NCT01218867)
- 2016-06-27Results posted on the registry: National Cancer Institute (NCI), Anti-NY ESO-1 T-cell receptor PBL + aldesleukin (NCT00670748)
- 2015-08-24Results posted on the registry: Jorge A. Garcia, MD, aldesleukin + bevacizumab (NCT00853021)
- 2015-07-03Results posted on the registry: Masonic Cancer Center, University of Minnesota, aldesleukin + natural killer cells (NCT00303667)
- 2015-04-13Results posted on the registry: Peking University People's Hospital, Interleukin-2 (NCT02084238)
- 2015-04-08Phase 3 first posted: Adienne SA, Begelomab + Conventional Second-line Treatment (NCT02411084)
- 2015-02-19Results posted on the registry: National Cancer Institute (NCI), Aldesleukin + Dinutuximab (NCT01041638)
- 2014-12-17Results posted on the registry: Wake Forest University Health Sciences, Tumor Infiltrating Lymphocytes (TIL) (NCT00863330)
- 2014-10-30Phase 3 first posted: The Netherlands Cancer Institute, Cyclophosphamide + Fludarabine (NCT02278887)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision